Molecular diagnostics leader and cancer center's Moon Shots Program launch initiative to identify lung cancer in early stages MD Anderson News Release 06/04/2015 Exact Sciences Corp. and The University of Texas MD Anderson Cancer Center today announced an agreement to jointly develop and commercialize blood-based screening and diagnostics tests for the early detection of lung cancer. This unique collaboration seeks to build upon MD Anderson's extensive research into predictive biomarkers for lung cancer and Exact Sciences' successful development and commercialization of Cologuard®, the only FDA-approved, non-invasive colon cancer screening test. The two groups plan to develop a groundbreaking new blood test that targets biomarkers associated with lung cancer.